YS Biopharma Co., Ltd. YS
Day range unavailable
52-week range unavailable
- Market cap
- 192.09M
- Revenue (ttm)
- 544.09M
- Profit margin
- -66.77%
- Shares out
- 188.33M
- Forward P/E
- -4.08
- Beta
- 0.54
- Analysts
- Buy
- Price target
- 4.17 (+308.8%)
- Earnings date
- Apr 19, 2024
6M +0.2050 (+40.20%)
Key statistics
- Enterprise value
- 429.47M
- PEG ratio
- 0.00
- Price / sales
- 0.35
- Price / book
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -9.20%
- Free cash flow
- 0
- Total cash
- 222.61M
- Total debt
- 558.09M
- Return on equity
- -77.80%
- Short % of float
- 0.03%
- 50-day average
- 0.865072
- 200-day average
- 0.663085
Analyst view
Consensus: buy
- Target (low)
- 3.10
- Target (mean)
- 4.17
- Target (high)
- 5.25
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 19, 2024
Expected Apr 19, 2024. Consensus EPS estimate -0.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 19, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Jan 22, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
About YS Biopharma Co., Ltd.
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- ysbiopharm.com
News
YS Biopharma Announces Name Change to LakeShore Biopharma 
YS Biopharma Announces Results of Extraordinary General Meeting 
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer 
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule 
YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript 
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine 
YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine 
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
Your note
Sign in to keep a note on YS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 3.58% | 4,298,465 | 5.93M | Jun 29, 2023 |
| FIL LTD | 2.27% | 2,718,499 | 3.75M | Jun 29, 2023 |
| Valliance Asset Management Ltd | 1.34% | 1,607,175 | 2.22M | Jun 29, 2023 |
| FMR, LLC | 0.97% | 1,165,071 | 1.61M | Jun 29, 2023 |
| HHLR Advisors, LTD | 0.63% | 751,790 | 1.04M | Jun 29, 2023 |
| Snow Lake Management LP | 0.30% | 357,149 | 492.87K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 13,608 | 20.55K | May 30, 2023 |